Investor
The company's Synapsis AI platform automates complex data readings, which allows for more efficient and optimal clinical research.
The funding includes $4.5 billion for the firm's core VC funds, $1.5 billion for its Creation strategy and $2 billion for separately managed accounts.
The message-based platform allows patients to get answers to complex medical questions, receive second opinions, seek urgent care and obtain assistance with end-of-life decisions.
The newly released PDTs, now RESET and RESET-O, deliver a self-directed, 12-week course of cognitive behavioral therapy that incentivizes patients to conform to treatment.
The New York-based company will use the investment to grow its partnerships and coverage among payers and move into Medicare populations in 2025.
The company helps FQHCs, STD and Ryan White clinics develop, operate and grow in-house pharmacy programs focused on HIV and Hepatitis C patient populations.
The company will be subject to a 12-month follow-up review period to assure that it does not fall below NYSE standards.
The company will use the funds to accelerate its product expansion on a global scale.
The Series A funding announcement comes less than a month after the company announced integration capabilities with AWS, Google Cloud, Databricks and Snowflake.
The company will use the funds to expand its partnerships with Athena, Oracle Cerner, Epic and MEDITECH, and to enhance its offerings, Suki Assistant and Suki Platform.